This paper reviews the studies in which neuromuscular blocking drugs were comapred in at least two different age groups of patients. Most recent studies have lead to a uniform concept of the variation of the effect of these drugs in different age groups. In general, the dose of a nondepolarizing agent required to produce a particular degree of relaxation is similar in neonates (less than one month), infants (one to twelve months) and adolescents (more than thirteen years). However, in children from three to ten years the dose is significantly greater. The maximal effect is reached more quickly in neonates and infants than in the older children and adolescents. These results can be explained by changes in sensitivity, distribution volume and muscle mass. The duration of effect of a nondepolarizing agent is significantly altered by age only in the case of vecuronium, which has a prolonged action in neonates and infants. Suxamethonium remains as the agent with the most rapid onset.
in a premature of 30 weeks postconceptual age. 4 Because the neonatal diaphragm has fewer type I fibres which are sensitive to neuromuscular blockers, the diaphragm would be expected to remain more active relative to peripheral muscles during neuromuscular block. It has been observed clinically that, during the recovery from muscle paralysis, diaphragmatic movements start at deeper levels of neuromuscular block in neonates than in older children.
Neuromuscular blocking agents are distributed to a volume which mirrors the extracellular fluid compartment. During the first year of life, the distribution volume decreases when calculated as mUkg of body weight. 5 -8 At the same time, the plasma concentration of a nondepolarizing muscle relaxant required to maintain muscle paralysis may increase. The net effect of these two counteracting changes depends on the individual muscle relaxant used. Therefore, different muscle relaxants have slightly different age-dependent potencies. Furthermore, elimination of muscle relaxants from the body takes place via metabolism, renal excretion or spontaneous degradation. All these depend on the maturation of the elimination pathways leading to different age-dependent durations of effect of various muscle relaxants. There are several reasons why a patient may move or start to breathe during general anaesthesia even though the neuromuscular block apparently has been maintained at an adequate level when monitored with a peripheral nerve stimulator. Almost twice the amount of muscle relaxant is required to paralyse the diaphragm to the same level as the hand muscles ( Figure 1 ).9-11 During light anaesthesia, a patient can breathe, cough or respond to bronchial stimuli at deep levels of peripheral muscle relaxation. 12 Table 1 shows ED95 (doses which produce a 95% neuromuscular block) doses of nondepolarizing muscle relaxants in neonates, infants, children and Anaesthesia and Intensive Care. Vol. 18, No. 4, November, 1990 adolescents. These data have been taken from studies where at least two different paediatric age groups have been compared, Although several investigators have found that children require greater doses of nondepolarizing muscle relaxants (in mg/kg) than any other age group of patients (Table 1) , the observation has not been explained. Extracellular fluid volume, which mirrors the distribution volume of muscle relaxants, cannot offer a complete explanation because this volume (as a percentage of body weight) does not change much after the first year of life.
NONDEPOLARIZING MUSCLE RELAXANTS

Long-acting agents
Differences in the body composition during growth of children may explain the differences in dose requirement. After the first year of life there are major changes in the fat and muscle compartments of the human body. 13 The fat compartment increases by two to three times to its maxium of as much as 30% of body weight during the first year of life; thereafter, it diminishes towards puberty. The muscle compartment (as a percentage of body weight) decreases during the first year oflife. Later, it increases two or threefold in relation to body weight, until it reaches a maximum of 40% by the end of active growth phase. Adults have more fat and less muscle tissue in their body than children. Thus, when we give a drug on a body weight basis (in mg/kg), the greatest dose may be needed by children at the age when they have the least fat and the most muscle tissue (i.e receptors) compared with other age groups of patients.
The pattern of age-dependency of the dose requirement of d-tubocurarine was initially studied almost fifteen years ago. 14 During that study the patients received varying concentrations of halothane. No difference in the ED95 dose or in the duration of effect in neonates, infants and children was demonstrated. A more recent study showed that children require 21 % greater d-tubocurarine dose than infants to establish a 95% neuromuscular block. 15 The onset time of d-tubocurarine (time from intravenous administration to maximal effect) is shorter in infants than in children. 15 -16 Time to establish a 90% neuromuscular block was 1.6 and 5.2 min, respectively following a dose of 400 Ilg/kg during halothane anaesthesia. 16 Because onset is slow, a more rapidly acting drug may be preferable for endotracheal intubation.
Two recent paediatric pharmacokinetic studies on d-tubocurarine are conflicting with both demonstrating that neonates and infants have a larger distribution volume than children or adults. Fisher et al 5 showed that neonates and infants require lower plasma concentrations of curare than children or adults to maintain comparable neuromuscular block. In contrast, Matteo et al 6 did 15 ,17 not find any difference in the plasma concentrations of curare required to produce comparable neuromuscular block in neonates, infants, children or adults, Both studies showed that the elimination of d-tubocurarine is slower in neonates and infants than in children or adults, which results in prolonged duration of effect in infancy after multiple doses or a large single dose.
For both pancuronium and alcuronium the dose producing a 95% neuromuscular block is 30-35% less in infants than in children. 15, 17 Figure 2 shows the dose-response curves of long-acting muscle relaxants for infants and children. A consistent difference exists between the dose requirements of these age groups. In adolescents the dose requirement is 15-20% less than in children. When pancuronium or alcuronium are used during general anaesthesia without volatile agents, the first doses are generally 0.1 or 0.3 mg/kg, respectively. These are only slightly greater than the ED95 doses for children (0.093 and 0.28 mg/kg, respectively).
The maximal effects following these relaxants are reached faster in infants than in children or adults ( Table 2 ). For example, the time to 90% neuromuscular block following pancuronium 70 Ilg/kg during halothane anaesthesia increased from 1.3 to 2.7 min between infancy and 10 years of age. IS Following an initial dose, incremental doses of these relaxants are usually required within the next 30-45 minutes for maintenance of muscle relaxation.
Hourly requirements of pancuronium and alcuronium to maintain 95% neuromuscular block are 60 and 40% of their ED95 dose, respectively. 17, 19 This means that hourly pancuronium and alcuronium requirements in children are, on an average, 0.055 and 0.11 mg/kg, respectively.
Thus, surgical relaxation can be maintained for two to three hours by incremental doses of longacting nondepolarizing muscle relaxant totalling the same as the dose used for endotracheal intubation. In clinical practice, incremental doses of one-quarter to one-fifth of the initial first dose of these long-acting agents should be used. These increments are usually required every 30 to 40 minutes.
Both the first dose and the maintenance requirement for pancuronium and alcuronium are an average 30% less in infants than in children. The duration of neuromuscular block following an The data for pancuronium and vecuronium for adolescents are from adults. The data for atracurium are extrapolated from the studies 27-28. equipotent dose, such as an ED95 dose, is similar in infancy and childhood. 17 ,20 If a constant dose in mg/kg is used for all paediatric patients, it is occasionally difficult to reverse residual neuromuscular block at the end of a short anaesthetic, because such a dose is more potent in infants and neonates. These younger patients are particularly prone to postoperative problems such as compromised spontaneous breathing. Pancuronium tends to produce tachycardia and increase systemic blood pressure in children, as it does in adults. This is advantageous if other anaesthetic drugs which have cholinergic effects (e.g. high-dose fentanyl) are used simultaneously. Alcuronium has a slight negative inotropic effect and is not ideal for patients with existing myocardial failure. In children, as in adults, d-tubocurarine produces hypotension.
Intermediate-acting agents
Vecuronium and atracurium have been studied much more extensively in paediatric patients than long-acting muscle relaxants. Volatile anaesthetic agents (halothane < enflurane < isoflurane) decrease the dose requirement of these agents and prolong the duration of neuromuscular block by an average of 30%.21.24 The age-dependency of dose requirement for vecuronium is greater than for atracurium. ED95 of vecuronium is 40% less in neonates and infants and 30% less in adolescents than in children (Table 1) . [24] [25] [26] The ED95 of atracurium is 30% less in neonates and infants than in children, with adolescents requiring similar doses to those in children. 27 ,28 When vecuronium is used to establish muscle relaxation during general anaesthesia with no volatile anaesthetic agent, the first dose is commonly 100 Ilg/kg. This dose is ideal only for children and should be reduced to 70 Ilg/kg in neonates and infants. Whereas the hourly requirement of vecuronium to maintain 95% neuromuscular block is 180-200% of the individual ED95 in children and adolescents, it is only 130% in neonates and infants.29 Therefore, vecuronium is not an intermediate-acting muscle relaxant in neonates or infants, but has a long-acting neuromuscular blocking effect. 30 Table 3 shows the duration of effect and the rate of spontaneous recovery of neuromuscular block following vecuronium in different age-groups of
The recovery index (spontaneous recovery time from 25 to 75% twitch height) and the duration of effect (time from administration to 90-100% recovery of the twitch height) following vecuronium in paediatric patients. Times are in minutes.
Ref
Recovery index Duration of effect Infants
Children Adolescents  Infants  Children  Adolescents   31  20  9  13  73  35  53  32  18  10  33  29  11  78  33  34  21  7  9  98  35  45 Halothane anaesthesia with 70 Ilglkg ofvecuronium was used in studies 31-32 as compared to nitrous oxide and opioid anaesthesia and a dose of 100 Ilglkg in studies 33-34. In studies 31, 33 and 34 the effect was followed until 90, 95, and 100% twitch height recovery, respectively. Meretoja et af. 39 Note that in infants the duration of neuromuscular block is significantly longer following a constant dose ofvecuronium but the difference following atracurium is clinically insignificant.
paediatric patients. The rate of twitch height recovery and the duration of effect are comparable following 70 ~g/kg during halothane anaesthesia and 1 00 ~g/kg during anaesthesia without any volatile agent. 31 -34 The age-related time differences are clinically very important. The rate of twitch height recovery is about 50% slower in infants than in children. Consequently, the duration of effect following a constant dose of vecuronium is more than 100% longer in infants than in children. 30 ,31,33,34 Thus, the elimination half-life of vecuronium may be longer in infants than in children. 8 The studies where this was measured did not take into consideration that the ED95 in infants is less than in children so that the doses used were not equipotent. In children, 70 ~g/kg during halothane anaesthesia and 1 00 ~g/kg during balanced anaesthesia, are only slightly more than ED95 dose. Spontaneous recovery following these doses takes place during the distribution phase of the drug in the body. 35 This results in short duration and fast recovery. On the contrary, the same doses are approximately twice ED95 dose in infancy and the spontaneous recovery of twitch height takes place during the elimination phase of the drug. 36 This explains the long duration and slow recovery in infancy.
Following an initial vecuronium dose of 100 ~g/kg in children, the next increment is usually required within twenty minutes. If subsequent doses are one-third of the initial dose, then these doses are required every 10 to 15 minutes. In neonates and infants, following an initial dose of 70 ~g/kg, the next increment is required within 30-40 minutes. If subsequent doses are one-third of this initial dose then they are needed on an average every 20 to 30 minutes. During halothane anaesthesia, the doses should be reduced by 30% (Table 3 ). Vecuronium has the advantage that it has no significant cardiovascular effects.
Atracurium is at present the only available intermediate-acting neuromuscular blocking agent for all groups of paediatric patients. The rate of spontaneous recovery following a constant dose (in mg/kg) of atracurium is little affected by the age of the patient. 22.27,37-39 In some studies, the duration of effect following either constant or equipotent dose of atracurium has been slightly shorter,38 similar 22 ,27,37 or slightly longer 39 in infants compared to children or adolescents. The differences in the duration of effect has always been less than 25% and are therefore of no significant clinical importance. Figure 3 shows the spontaneous recovery rate of twitch height following either 1 00 ~g/kg of vecuronium or 400 ~g/kg of atracurium in infants and children. Note the important difference in the duration of effect in infancy.
Four groups of investigators have determined the ED95 of atracurium in paediatric patients. The dose-values are somewhat different, although there is general agreement on the influence of age on EDvalues. Studies where mechanical force has been used show an ED95 for children of 200-230 ~g/kg, 22.27 whereas studies using electromyography show a value of 320-350 ~g/kg21,28 during balanced anaesthesia. Corresponding values for infants are 160 and 230 ~g/kg, respectively.27,28 If these results are used clinically, a sufficient initial dose of atracurium for a child would be 400 ~g/kg during balanced anaesthesia. This dose is often more than 1.5 times ED95 dose and produces good intubating conditions within two minutes following intravenous administration. During halothane anaesthesia, the initial dose could even be 300 ~g/kg. The greater the initial dose of atracurium, the more histamine is likely to be released into the circulation. The amount of histamine liberation and the severity of untoward reactions caused by it are less in children than in adults. 4o Because histamine release can be minimised by decreasing the dose of atracurium, it is unnecessary to administer greater doses than those mentioned above. High doses may be associated with hypotension, particularly if the dose is administered rapidly.
To maintain a 95% neuromuscular block during balanced anaesthesia without any volatile agent, the hourly atracurium requirement is 500 ~g/ kg. 23 ,41,42 This dose requirement has been demonstrated consistently in studies evaluating neuromuscular block either by force or electromyography. In infants the infusion Onset time Age. years requirement is similar to that of children,42,43 but neonates require 25% less. If atracurium is not used by continuous infusion, but as incremental bolus dosages during the maintenance of anaesthesia, then increments of one-third the initial dose are required approximately every fifteen minutes. Maximum neuromuscular blocking effects following all muscle relaxants occur faster in neonates and infants than in children or adolescents (Table 2) . 15, 18, 28, 31 The onset times of different muscle relaxants are dose-dependent: the maximum effect following atracurium 150 Ilg/kg is reached in three minutes in neonates and infants and only in 5.5 minutes in children and adolescents. The respective onset times are 1.0 and 1.5 minutes, following a 500 Ilg/kg dose (Figure 4) .
Short-acting agents
The only short-acting nondepolarizing muscle relaxant which has been on clinical trial is mivacurium, an agent whose molecular structure is related to atracurium. The ED95 dose of mivacurium in children during balanced and halothane anaesthesia is 110 and 90 Ilg/kg, respectively.44,45 These doses are 30-40% greater than the ED95 dose for adults. 46 The dose of mivacurium to maintain a 95% neuromuscular block is six to eight times the individual ED95 dose per hour. 47 ,48 The duration of effect following mivacurium 100 Ilg/kg is more than twice as long as the duration following 1 mg/kg of suxamethonium. The time from intravenous administration to maximal effect is also longer with mivacurium. The onset time of mivacurium following twice ED95 dose is more than 1.5 minutes. 44 ,45 Thus, the search continues for a nondepolarizing neuromuscular blocking agent with as short an onset time as that of suxamethonium.
DEPOLARIZING MUSCLE RELAXANTS
Suxamethonium
Suxamethonium is still the muscle relaxant with the shortest onset time ( Table 2 ). It is especially indicated when rapid endotracheal intubation is required, for example in patients with full stomachs. In contrast to nondepolarizing muscle relaxants, the dose requirement ofsuxamethonium is greater in neonates and infants than in children or adolescents ( Figure 5 ).49-51 Separate studies have shown that infants have an ED95 value 70% greater than children (730 vs. 420 llg/kg)50 and adolescents half that for children (270 vs. 450 llg/kg)51 but comparable to adults_ 52 A dose of 1.5-2_0 mg/kg is commonly used for neonates and infants, compared with 1.0-1.5 mg/kg in older patients, to establish muscle relaxation sufficient for endotracheal intubation. These doses are several times ED95 but give a longer period of muscle relaxation than the minimal possible intubating dose. 5 0, 51 Goudsouzian et at. 53 found that young infants (mean age of two months) required a much greater infusion rate of suxamethonium than older infants (mean age of 6 months) to maintain a 95% neuromuscular block_ The infusion rates during halothane anaesthesia were 25 and 9 mg/kg/h, respectively _ Both these rates were greater than that required by children (6 mg/kg/h). Adequate neuromuscular monitoring was regarded as imperative during suxamethonium infusion because of great individual variation in the response.
Fasciculations and myoglobinuria after suxamethonium are uncommon in patients under two years of age. Other side-effects of suxamethonium include increased intracranial and intraocular pressure. Dysrhythmias following suxamethonium, especially bradycardia during inhalational anaesthesia, are common. These more frequently follow repeated doses. The incidence of bradycardia can be reduced by giving atropine 10 ~g/kg (in infancy 20 ~g/kg) before the relaxant. Normally, serum potassium rises 0.1 to 0.2 mmoVI following suxamethonium 1 mg/kg. In large burns, massive release of potassium between the second and sixth week may cause rises in serum potassium (over 4 mmol/l) sufficient to cause cardiac arrest. The extent ofthe rise is related to the burn area and the dose. 54 Hyperkalaemia may also occur in patients with spinal injuries or following major trauma. Hyperpyrexia may occur in susceptible patients.
REVERSAL OF MUSCLE RELAXATION
Before any change in neuromuscular transmission can be recorded by the monitors currently available, 75% of receptors must be occupied by a nondepolarizing relaxant. At the time of 95% block, 90% of receptors are occupied. To ensure adequate spontaneous respiration in the postoperative period, neuromuscular block should be reversed, as residual blockade may be undetected and the reserve of muscular power be decreased.
The classical antagonist for nondepolarizing muscle relaxants is neostigmine. The dose requirement to reverse d-tubocurarine induced neuromuscular block is less in paediatric patients than in adults, while its elimination is more rapid. 55 The dose of 50 ~g/kg can be used for all paediatric age groups, together with atropine 20~g/kg or glycopyrrolate 1 0 ~g/kg. The maximum effect of neostigmine usually is not reached until five to ten minutes after intravenous administration, although the patient is usually extubated much earlier. 56 ,57 If 25 ~g/kg is used, recovery time is doubled. 58 The time taken to reach full muscle power after neostigmine is much longer when a long-acting rather than an intermediate-acting relaxant is used. 59 Edrophonium has a significantly shorter onset time than neostigmine. 56 ,57,60 The elimination of edrophonium from the body may be faster, but the potency less in infants and children than in adults.60 Therefore, the dose of edrophonium may be 1.0 mg/kg for all paediatric patients. This effectively reverses neuromuscular block, if twitch height before reversal is > 10% (2-3 twitch responses after train-of-four stimuli).56,57 If neuromuscular block is deeper at reversal, then neostigmine has a more potent effect than edrophonium.
RECOMMENDATIONS FOR DOSAGE OF NEUROMUSCULAR BLOCKING AGENTS
Only the most recent studies have made it possible to give reliable recommendations on dosage for the neuromuscular blocking agents used in paediatric anaesthesia. An intial dose of any nondepolarizing muscle relaxant which exceeds 1.3 to 1.5 times the individual ED95 dose may produce an unnecessarily long-lasting effect. The recommendations in Table 4 are based on those in Table 1 , but are modified so that doses greater than Anaesthesia and Intensive Care, Vol. 18, No. 4, November, 1990 necessary are avoided, especially with long-acting agents. If a dose is given which exceeds twice the ideal individual dose, the duration of effect is prolonged by the time equal to the elimination halflife ofthat agent. In the case of atracurium this time is twenty minutes, but in the case of pancuronium or alcuronium this time may be as much as two or three hours.
When the maintenance requirements of different muscle relaxants are derived in relation to individual ED95 doses, the hourly dose has a constant relationship through the paediatric age range, except for vecuronium. In that case, the requirement for infants under one year is one-third less than for older children. This indicates that vecuronium is longer-acting in infants than in older patients ( Table 5 ).
